Author Archives: admin


Stem Cell Clinic > Articles by: admin

PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

By Global News Feed

TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) is disappointed in the decision made by the US Food and Drug Administration (USFDA) to request that Lykos Therapeutics complete a third confirmatory Phase 3 trial prior to allowing the approval of MDMA assisted therapy (MDMA-AT) for the treatment of Post Traumatic Stress Disorder.

See the original post:
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

By Global News Feed

Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024

See the rest here:
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

By Global News Feed

BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- eLabNext, an Eppendorf Group Company offering a flexible Digital Laboratory Platform equipped with a Laboratory Inventory Management System (LIMS) and Electronic Lab Notebook (ELN), announced today that they’ve entered into a “preferred vendor” partnership with US Lab Partners, a strategic consulting and advisory firm that provides life sciences companies with best-in-class labs, facilities, and EH&S programs.

Read the original post:
eLabNext and US Lab Partners Enhance Digital Infrastructure for Life Science Companies

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Global News Feed

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 40,350 shares, and restricted stock units (RSUs) covering an aggregate of 28,200 shares, of BioCryst common stock. The options and RSUs were granted as of July 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Read this article:
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

By Global News Feed

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 2:00 p.m. ET.

See more here:
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET

By Global News Feed

HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time.

See more here:
Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET

→←